Singulex’s Assay for Cardiovascular Risk Assessment Highlighted in Two Presentations at AHA 2013 Scientific Sessions

28-11-2013 Business Wire HealthComments (0)

Anti-Arthritics/RheumaticsBiotechnologyCardio-vascular

Singulex, Inc., the developer and leading provider of Single Molecule Counting (SMC™) technology for clinical diagnostics and scientific discovery, today announced new data highlighting the Company’s ultrasensitive Erenna® Immunoassay System in the detection of cardiac troponin-I (cTnI). Two studies utilized the Erenna System to measure previously undetectable levels of cTnI in order to assess cardiovascular disease risk in rheumatoid arthritis (RA) and heart f

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top